The spotlight has been on Keytruda at cancer congresses for a decade or so, and it was no different at the European Society for Medical Oncology meeting in Barcelona, Spain, with the presentation of new positive overall survival (OS) data in the earlier stages of two types of women’s cancers for Merck & Co., Inc.'s behemoth standing out.
ESMO 24: Keytruda Shows Strong OS Benefit In Two Women's Cancers
Merck & Co has presented lots of data on its huge-earning checkpoint inhibitor at the Barcelona congress, the highlights being impressive first-time overall survival results for Keytruda in cervical cancer and early-stage triple-negative breast cancer.
